CN115927643A - Application of hsa _ circ _0001495 molecule in liver cancer treatment - Google Patents
Application of hsa _ circ _0001495 molecule in liver cancer treatment Download PDFInfo
- Publication number
- CN115927643A CN115927643A CN202310066644.XA CN202310066644A CN115927643A CN 115927643 A CN115927643 A CN 115927643A CN 202310066644 A CN202310066644 A CN 202310066644A CN 115927643 A CN115927643 A CN 115927643A
- Authority
- CN
- China
- Prior art keywords
- circ
- hsa
- liver cancer
- drugs
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 72
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 70
- 230000014509 gene expression Effects 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 9
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 9
- 150000007523 nucleic acids Chemical group 0.000 claims abstract description 9
- 108091028075 Circular RNA Proteins 0.000 claims abstract description 8
- 238000003745 diagnosis Methods 0.000 claims abstract description 8
- 229940079593 drug Drugs 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 6
- 239000000126 substance Substances 0.000 claims abstract description 6
- 238000012165 high-throughput sequencing Methods 0.000 claims abstract description 3
- 230000002401 inhibitory effect Effects 0.000 claims abstract 2
- 239000000523 sample Substances 0.000 claims description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 2
- 206010017758 gastric cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 108700024394 Exon Proteins 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 210000003917 human chromosome Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 238000010396 two-hybrid screening Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 abstract description 6
- 238000012827 research and development Methods 0.000 abstract description 3
- 238000012360 testing method Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 54
- 210000001519 tissue Anatomy 0.000 description 23
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 11
- 238000013508 migration Methods 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000005012 migration Effects 0.000 description 10
- 238000006243 chemical reaction Methods 0.000 description 9
- 239000003153 chemical reaction reagent Substances 0.000 description 9
- 238000011529 RT qPCR Methods 0.000 description 8
- 108020004459 Small interfering RNA Proteins 0.000 description 8
- 230000009545 invasion Effects 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 238000003753 real-time PCR Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000005228 liver tissue Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000002018 overexpression Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000003197 gene knockdown Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 239000004055 small Interfering RNA Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000001890 transfection Methods 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 101000852613 Homo sapiens Importin-11 Proteins 0.000 description 3
- 102100036399 Importin-11 Human genes 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000004709 cell invasion Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 239000013603 viral vector Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000003235 crystal violet staining Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000013399 early diagnosis Methods 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108091058104 miR-187 stem-loop Proteins 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 229950010131 puromycin Drugs 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101150071041 Ccnb1 gene Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102100024607 DNA topoisomerase 1 Human genes 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 229920000209 Hexadimethrine bromide Polymers 0.000 description 1
- 101000830681 Homo sapiens DNA topoisomerase 1 Proteins 0.000 description 1
- 101001094554 Homo sapiens Rhotekin-2 Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102100035117 Rhotekin-2 Human genes 0.000 description 1
- 108010016200 Zinc Finger Protein GLI1 Proteins 0.000 description 1
- 102100035535 Zinc finger protein GLI1 Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 210000001808 exosome Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 238000009650 gentamicin protection assay Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009459 hedgehog signaling Effects 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 238000010232 migration assay Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003147 molecular marker Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- -1 small molecule compounds Chemical class 0.000 description 1
- 230000008410 smoothened signaling pathway Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention belongs to the field of biological medicine, and relates to application of a circular RNA hsa _ circ _0001495 in liver cancer treatment, in particular to application of an hsa _ circ _0001495 molecule as a diagnosis marker in liver cancer treatment or application as a target in research and development of anti-cancer drugs; the hsa _ circ _0001495 molecule is a circRNA molecule highly expressed in liver cancer tissues, and the nucleic acid sequence of the circRNA molecule is SEQ ID NO.1. The products for diagnosing liver cancer comprise a chip, a kit, test paper or a high-throughput sequencing platform and the like. The anti-cancer drugs comprise gene drugs and chemical drugs for inhibiting the expression of hsa _ circ _ 0001495.
Description
Technical Field
The invention belongs to the field of biological medicines, and relates to application of an hsa _ circ _0001495 molecule in liver cancer treatment, in particular to application of the hsa _ circ _0001495 molecule as a diagnosis marker in liver cancer treatment or application as a target in research and development of anti-cancer drugs.
Background
Primary liver cancer is one of the most common malignant tumors in clinic, and the incidence rate is the fourth of the malignant tumors. Hepatocellular carcinoma is the most common one of primary liver cancers, accounting for about 85% -90%. Surgical resection, radiotherapy and chemotherapy are the most common means of treating liver cancer, but have limited effect on middle and late stage liver cancer patients. A large number of clinical results prove that the survival period of the liver cancer patient for early diagnosis and proper treatment is longer than that of the patient for diagnosis and treatment after the relevant symptoms appear. Therefore, the method is very important for early screening and prognosis judgment of liver cancer patients. The molecular mechanism of liver cancer is searched, and a new therapeutic target and means are searched, which has important significance for the clinical treatment of liver cancer.
Circular RNA (circular RNA) is a kind of non-linear single-stranded non-coding RNA, and the heads and the tails of the circular RNA are combined through covalent bonds to form a closed circular structure. The circular structure of the circRNA is not easily degraded by exonuclease, so that the circular structure is more stable and has longer half-life. circRNA is abundant, conserved, stably expressed in saliva, blood and exosomes, and exhibits tissue developmental stage specificity, which makes it promising as a cancer biomarker. In recent years, a number of studies have shown that circRNA plays an important role in the process of tumor development. The document (Gu Y, wang Y, he L, et al. Circular RNA circular IPO11 drive self-reverse of liver initiating cells via Hedgehog signaling [ J ]. Mol Cancer,2021,20 (1): 132) found that circular IPO11 is highly expressed in liver Cancer tumor tissue, and that circular IPO11 triggers its transcription by recruiting TOP1 to GLI1 promoters, leading to activation of the Hedgehog signaling pathway, driving self-renewal of liver CSCs, and promoting liver Cancer progression. Furthermore, huang et al (Huang G, liang M, liu H, et al, circRNA hsa _ circRNA _104348 proteins hepatocellular cancer promotion and modulation miR-187-3p/RTKN2 a and activivating Wnt/beta-catenin pathway [ J ]. Cell Death Dis,2020,11 (12): 1065) found that hsa _ circRNA _104348 is also significantly up-regulated in liver cancer tissues and cells, has _ circ _104348 directly targets miR-187-3p to promote proliferation, migration and invasion of liver cancer cells, and simultaneously inhibits apoptosis of liver cancer cells. The research results show that the circRNA is related to metastasis, recurrence, survival and the like of the liver cancer patient and is a promising marker for diagnosis and prognosis of the liver cancer patient. In addition, in the case of the circRNA, a complex signal path and a series of chain reactions which influence the regulation and control of liver cancer progress also need to be deeply excavated, so that theoretical guidance is provided for further exploring the pathogenesis of liver cancer.
We find that the novel circRNA is highly expressed in liver cancer tissues and blood, and the novel circRNA can inhibit the tumorigenicity of liver cancer cells through targeted regulation and control. Experimental results show that the novel circRNA is a potential molecular marker for early diagnosis and prognosis of liver cancer, is also an important molecular target for targeted therapy of liver cancer, and has important clinical significance for treatment of liver cancer.
Disclosure of Invention
In order to realize the purpose of the invention, the invention provides application of the hsa _ circ _0001495 molecule as a diagnostic marker in liver cancer treatment or as a target in research and development of anti-cancer drugs.
The hsa _ circ _0001495 molecule is a circRNA molecule highly expressed in liver cancer tissues, the nucleic acid sequence of the circRNA molecule is SEQ ID NO.1, and the specific information is as follows:
AATAATTGTGTGCCCAAGAAGATGCTGCAGCTGGTTGGTGTCACTGCCATGTTTATTGCAAGCAAATATGAAGAAATGTACCCTCCAGAAATTGGTGACTTTGCTTTTGTGACTGACAACACTTATACTAAGCACCAAATCAGACAGATGGAAATGAAGATTCTAAGAGCTTTAAACTTTGGTCTGGGTCGGCCTCTACCTTTGCACTTCCTTCGGAGAGCATCTAAGATTGGAGAGGTTGATGTCGAGCAA CATACTTTGGCCAAATACCTGATGGAACTAACTATGTTGGACTATGACATGGTGCACTTTCCTCCTTCTCAAATTGCAGCAGGAGCTTTTTGCTTAGCACTGAAAATTCTGGATAATGGTGAATGG。
the invention provides an application of hsa _ circ _0001495 molecules as diagnostic markers in preparing products for diagnosing liver cancer. As a preferable technical scheme of the invention, the product for diagnosing the liver cancer at least comprises a PCR amplification primer used for detecting the expression quantity of hsa _ circ _0001495 by using SYBR Green, a TaqMan probe, a double-hybrid probe or a composite probe.
In a specific embodiment of the present invention, the specific information of the sequences of the PCR amplification primers is as follows:
Forward primer TGGTGAATGGAATAATTGTGTGCC
Reverse primer AGGAAGTGCAAAGGTAGAGGC
furthermore, the products for diagnosing liver cancer comprise a chip, a kit, test paper or a high-throughput sequencing platform and the like; the preparation method of the product is a technical method known to the person skilled in the art.
The kit comprises a reagent for detecting the expression amount of hsa _ circ _0001495, wherein the reagent comprises a nucleic acid combined with hsa _ circ _0001495 or a DNA sequence thereof, and the nucleic acid comprises SYBR Green, taqMan probe, molecular beacon, double-hybrid probe or PCR amplification primer used when a composite probe detects the expression amount of hsa _ circ _ 0001495.
The chip comprises a reagent for detecting the expression level of hsa _ circ _0001495, wherein the reagent comprises a nucleic acid combined with hsa _ circ _0001495 or a DNA sequence thereof, and the nucleic acid comprises a probe capable of detecting the expression level of hsa _ circ _ 0001495.
The test strip comprises a reagent for detecting the expression level of hsa _ circ _0001495, wherein the reagent comprises a nucleic acid combined with hsa _ circ _0001495 or a DNA sequence thereof, and the nucleic acid comprises a probe capable of detecting the expression level of hsa _ circ _ 0001495.
As another invention point of the invention, the invention also provides the application of the hsa _ circ _0001495 molecule as a target in the development of anti-cancer drugs.
As a preferred technical scheme of the invention, the anti-cancer drugs comprise gene drugs and chemical drugs, such as inhibitors, which inhibit the expression of hsa _ circ _ 0001495.
Further, the inhibitor is not limited as long as it can inhibit the expression level of hsa _ circ _0001495 or inhibit the functional activity of hsa _ circ _ 0001495.
The inhibitor comprises hsa _ circ _0001495 molecules, repressible transcription regulatory factors or repressible targeted small molecule compounds.
The gene medicine or chemical medicine produced by the invention can be applied to one or more of liver cancer, lung cancer, colorectal cancer, gastric cancer, breast cancer and the like.
The gene medicine or chemical medicine comprises a pharmaceutically acceptable carrier in a clinically acceptable form.
Compared with the prior art, the invention has obvious technical effect
The hsa _ circ _0001495 molecule provided by the invention is abnormally and highly expressed in liver cancer tissues and blood, is related to the malignancy degree of tumors, and can be used as a marker for auxiliary diagnosis of liver cancer. In addition, experiments prove that the overexpression of hsa _ circ _0001495 can obviously promote the proliferation and invasion and migration of the liver cancer cells, and the knock-down of hsa _ circ _0001495 can obviously inhibit the invasion and migration of the liver cancer cells and can be used as a potential target spot for treating liver cancer.
Drawings
FIG. 1: hsa _ circ _0001495 is a circular RNA. Wherein, FIG. A is a schematic structural view of hsa _ circ _ 0001495; panel B shows the sequencing results for hsa _ circ _0001495 showing the linker sites; panel C shows the PCR results of hsa _ circ _0001495 in different liver cancer cell lines; panel D shows FISH experiments that hsa _ circ _0001495 is distributed mainly in the cytoplasm.
FIG. 2: detecting the expression level of hsa _ circ _0001495 in the clinical specimen. Wherein, the graph A is a graph of the detection result of the expression level of hsa _ circ _0001495 in liver tissue and liver cancer tissue of a liver cancer patient; FIG. B is a graph showing the results of measuring the expression level of hsa _ circ _0001495 in liver tissues and liver cancer tissues of liver cancer patients at different pathological stages, wherein Normal represents the liver tissues, and I, II, III, and IV represent the different pathological stages of the liver cancer tissues; FIG. C shows the results of measurement of the expression level of hsa _ circ _0001495 in blood of normal persons and in blood of patients with liver cancer; * P < 0.01, p < 0.001.
FIG. 3: after overexpression of hsa _ circ _0001495, proliferation, survival, invasion and migration of the liver cancer cell line SK-HEP-1 were promoted. Wherein, the picture A shows that after the lentivirus transfection, the hsa _ circ _0001495 overexpression is detected by qRT-PCR; FIG. B is a graph showing the results of a cell clone survival experiment; FIG. C is a diagram showing the results of a CCK-8 cell proliferation assay; lv-NC stands for negative control group; FIG. D is a graph showing the results of a transwell cell invasion migration experiment; lv-circ _0001495 represents overexpression set; * p < 0.05, p < 0.01.
FIG. 4: after the hsa _ circ _0001495 is knocked down, the invasion and migration of the hepatoma cell SK-HEP-1 are inhibited. Wherein, the graph A shows the effect of detecting the knockdown of hsa _ circ _0001495 by qRT-PCR; FIG. B is a graph showing the results of a transwell cell invasion migration experiment; si-NC stands for negative control group; si-circ _0001495 represents the knockdown hsa _ circ _0001495 group, p < 0.05, p < 0.01.
Detailed Description
The invention is further described below by way of examples, which include the use of materials and specific sources. It should be understood that these are exemplary only, and are not limiting upon the present invention. Materials of similar or identical nature or function to the reagents, types and models of instruments, or the like, as described below, may be used in the practice of the present invention. Unless otherwise indicated, the reagents used in the present invention may be any suitable commercially available reagent.
Human hepatoma cell line SK-HEP-1: purchased from the national academy of sciences cell bank of the culture Collection; MEM medium: purchased from Invitrogen under catalog number 11965-092; serum: from Gibco, catalog number 10099-141; pancreatin: available from Invitrogen under product catalog number 25300-354; the overexpression plasmid and siRNA of hsa _ circ _0001495 were constructed by Shanghai Jima Biotechnology GmbH. The methods in the following examples are general methods unless otherwise specified.
Example 1 detection of hsa _ circ _0001495 expression by real-time fluorescent quantitative PCR (qRT-PCR)
A schematic of the biological synthesis and structure of hsa _ circ _0001495 is shown in FIG. 1, where hsa _ circ _0001495 is formed by reverse splicing of exon 6,7 of the CCNB1 gene.
1. Collection of clinical samples
The laboratory collected liver cancer tissues and paracancer normal liver tissues of 35 primary liver cancer patients, blood samples of 7 liver cancer patients and blood samples of 6 normal people from Huai river hospital and Kaifeng tumor hospital affiliated to Henan university in 2018. The tissue and blood specimens were snap frozen by liquid nitrogen and transferred to a-80 ℃ freezer. The whole collection and subsequent experimental process meets the medical ethical and moral requirements and strictly follows the confidentiality principle of case data.
RNA extraction and real-time fluorescent quantitative PCR (qRT-PCR)
(1) Extracting RNA
And (3) quickly freezing the taken liver tissue, liver cancer tissue, blood sample and liver cancer cell line by liquid nitrogen, and storing in a refrigerator at-80 ℃ for later use. Taking a proper amount of frozen tissues, adding tri-regent, and cracking cells by using a tissue disruptor; adding BCP layered cell/tissue lysate, centrifuging at 12000g 15min at 4 ℃, transferring the supernatant into a new EP tube, adding 2-protocal (isopropanol) (2-protocal: supernatant = 1), mixing uniformly for 10 times, and standing for 10min to fully separate out RNA; 12000g,10min,4 ℃ centrifugation, abandoning the supernatant, adding 75 percent DEPC ethanol 1ml, washing RNA once, slightly blowing up, 7500g, 5min, 4 ℃ centrifugation; the supernatant was aspirated off, dried on a clean bench for 10min, 20ul of nuclease-free water was added and placed in a 55 ℃ water bath for 10min, after full dissolution, the OD260 and OD280 absorption values were determined, generally considering that A260/A280 between 1.8-2.1 could be initially determined as good total RNA quality, and stored in a-20 ℃ freezer.
(2) RNA reverse transcription cDNA
Sample adding sequence: h 2 O-RNA-Random hexamer, reaction system is shown in Table 1.
TABLE 1 reaction System
Mixing, micro-separating, and placing the PCR tube in a PCR instrument at 65 deg.C for 5min.
The reaction system is shown in Table 2
TABLE 2 reaction System
After mixing, adding into the PCR tube, mixing and micro-separating. The PCR tube was placed in a PCR instrument at 42 ℃ for 90min and 95 ℃ for 5min. After the reaction, the cDNA was stored in a-20 ℃ refrigerator.
(3) Primer design
Primers for hsa _ circ _0001495 were designed using Primer Express Version3 software as follows:
Forward primer TGGTGAATGGAATAATTGTGTGCC
Reverse primer AGGAAGTGCAAAGGTAGAGGC
(4)real-time PCR
the cDNA was diluted to 4 ng/. Mu.L as a template for the fluorescent quantitative PCR reaction. Amplification was performed on an ABI 7500 fluorescent quantitative PCR instrument using forward primers, reverse primers and 2 XSSYBR Green qPCR mix for hsa _ circ _0001495, the reference gene.
The reaction system is shown in Table 3
TABLE 3 reaction System
The PCR conditions were: 20 seconds at 50 ℃; 10 minutes at 95 ℃;1 minute at 95 ℃;1 minute at 60 ℃ and 40 cycles were repeated; CT values of the sample hsa _ circ _ 0001495/internal reference gene amplification were determined.
3. Data processing and analysis
The ratio of the expression amounts of hsa _ circ _0001495 in liver tissues to that in liver cancer tissue samples was 2 -ΔΔCT The method carries out calculation. The specific results are shown in table 4 below:
TABLE 4 fluorescent quantitative PCR detection of expression levels of hsa _ circ _0001495 in liver and liver cancer tissues.
In Table 4, "1-12" is the first stage liver cancer tissue case, "13-20" is the second stage liver cancer tissue case, "21-28" is the third stage liver cancer tissue case, and "28-35" is the fourth stage liver cancer tissue case.
Statistical analysis by SPSS software revealed that hsa _ circ _0001495 has significant differences in expression levels in liver and liver cancer tissues (P < 0.001).
The results are shown in FIG. 2, qRT-PCR results show that hsa _ circ _0001495 is significantly up-regulated in liver cancer tissue compared to normal liver tissue and correlated with liver cancer malignancy. In addition, the expression of hsa _ circ _0001495 in the blood of liver cancer patients is also significantly higher than that of normal persons. Therefore, hsa _ circ _0001495 can be used as a marker for detecting liver cancer.
Example 2 Lentiviral vectors overexpressing hsa _ circ _0001495 promote proliferation, survival, invasion and migration of hepatoma cells
1. Viral vector construction
The cDNA sequence of hsa _ circ _0001495 was inserted into a lentiviral expression vector to construct a viral vector overexpressing hsa _ circ _ 0001495. The sequence map of hsa _ circ _0001495 was provided by the inventors, and the viral vector was constructed by Shanghai Jima science and technology Co., ltd.
2. Cell lines and cell cultures
Taking SK-HEP-1 cells of human hepatoma cell line, culturing with MEM supplemented with 10% fetal calf serum and 1% double antibody based on 5% CO 2 Culturing at 37 deg.C in incubator.
3. Viral transfection
(1) 18-24 hours before lentivirus transfection, adherent cells were plated at 1X 10 5 The/well was plated in 24-well plates. The number of cells in lentivirus transfection was 2X 10 5 About hole.
(2) The next day, the original medium was replaced with 2ml of fresh medium containing 6. Mu.g/ml polybrene, and an appropriate amount of virus suspension was added. Incubation was performed at 37 ℃.
(3) The culture was continued for 24 hours, and the virus-containing medium was replaced with fresh medium.
(4) And observing the fluorescence expression condition 72-96 h after infection.
(5) The cells were expanded in 12-well plates and cultured by selection with a medium containing 0.8. Mu.g/ml puromycin.
(6) The cells screened by puromycin are subjected to amplification culture, and after a part of cells are collected, the over-expression effect is detected by fluorescence quantitative PCR.
The qRT-PCR results of figure 3 show that the effect of lentiviral infection over-expressing hsa _ circ _0001495 (panel a) is significant.
4. Clone survival assay
(1) And (4) taking the cells of the experimental group and the control group for digestion and centrifugation, resuspending the cell sediment, and counting.
(2) The cell suspension is diluted to 150 cells/mL in an equal proportion gradient mode, 2mL of cell suspension is added into each hole of a 6-hole plate, 3 multiple holes are arranged, and the cell suspension is placed in a cell culture box for culture.
(3) After culturing for about two weeks, colonies of cells visible to the naked eye grew out. Washing with PBS for 3 times, fixing with 75% ethanol for 5min, discarding 75% ethanol, and air drying. 1mL of crystal violet staining solution was added to stain for 0.5h. The crystal violet staining solution was removed, washed 2 times with PBS, and the stained cell plates were photographed on white paper.
(4) Colony clone results analysis: colony clone numbers were counted and result trend comparisons were made.
5. Cell proliferation assay
(1) The digestion counts of the control and experimental groups of the stable transfected cells were counted.
(2) Add to 96-well plates labeled at different time points and each set was set with 3 multiple wells at each time point and put into a cell incubator.
(3) After 6h of cell adherence, 10 microliter of CCK-8 solution is added into a 96-well plate in a dark environment for incubation, and after 3h, the cells are taken out and measured on an enzyme-linked immunosorbent assay (ELISA) instrument for OD value at 450 nm.
(4) And measuring the OD values of the target cells at different time points by using the same method on a microplate reader, and drawing a curve according to the average value of the multiple wells at different time points.
Transwell cell migration assay
(1) Digesting and centrifuging the cells, discarding the culture medium, resuspending the cell precipitate with 1mL serum-free DMEM medium containing 0.05% -0.2% BSA, counting, and making the cells into the cells with the density of 2.5 × 10 5 The cell suspension of (3).
(2) The chamber was first moistened with serum-free MEM, 600. Mu.L of empty MEM was placed in a 24-well plate, the chamber was gently placed in the well, and then 200. Mu.L of MEM medium was aspirated and gently dropped into the chamber.
(3) After the chamber is wet, the MEM medium above and below the chamber is discarded. After adding 600. Mu.L of MEM complete medium to a 24-well plate, gently placing the chamber in the well with forceps (without generating air bubbles at the bottom of the chamber), 100. Mu.L of the homogenized cell suspension, i.e., 25000 cells per well, was added dropwise to the chamber, and the plate was placed in an incubator for culture.
(4) The cell is taken out and the result is collected when the cell is cultured for 44h, the cell is firstly placed in a new external 24-plate, the cell is firstly and softly cleaned by PBS for three times according to the standard that the volume of the upper cell is 100 mu L and the volume of the lower cell is 600 mu L, then the cell is placed in 4 percent paraformaldehyde for fixing for 10min, then the cell is cleaned by PBS for three times, finally 0.2 percent crystal violet is used for staining for 20min, after the staining is finished, the slow running water is used for washing and the cotton swab is used for wiping the cells on the upper surface of the cell, then the microscope is used for photographing and observing the condition of the cells transferred to the lower part of the cell, each sample is randomly beaten for 5 times, and the statistics is carried out by calculating the average value.
7. Data processing and analysis
The results were statistically analyzed using SPSS 23.0 software. Graph Pad Prism 7.0 software was used for mapping. Statistical analysis was performed using paired t-tests as appropriate. Data are presented as mean ± standard deviation of at least three independent experiments, with P < 0.05 considered statistically significant.
The results in FIG. 3 show that overexpression of hsa _ circ _0001495 promotes hepatoma cell proliferation, survival, invasion and migration.
Example 3 knockdown of hsa _ circ _0001495 inhibits invasion and migration of hepatoma cells to demonstrate that hsa _ circ _0001495 can be a novel target for treatment of hepatoma
1. Construction of Small interfering RNAs (siRNAs)
Specific small interfering RNA (siRNA) targeting hsa _ circ _0001495 reverse splice site and negative control (si-NC) were synthesized from the gimar gene (shanghai), and a sequence map of hsa _ circ _0001495 was provided by the inventors.
siRNA transfection
50nM siRNA was transfected into hepatoma cells using Lipofectamine 3000 (Invitrogen, carlsbad, calif., USA). And (3) detecting the interference effect by fluorescent quantitative PCR.
The qRT-PCR results of figure 4 show that the effect of siRNA knock-down of hsa _ circ _0001495 (panel a) is significant.
The results in FIG. 4 show that inhibition of hepatoma cell invasion and migration was achieved after knock-down of hsa _ circ _ 0001495. Proves that hsa _ circ _0001495 can be used as a new target for targeted therapy of liver cancer.
The above-described embodiments are merely exemplary and are merely preferred embodiments of the present invention, and the scope of the present invention is not limited thereto, and those skilled in the art can make various modifications and variations without departing from the technical principle of the present invention, and these modifications and variations should be construed as the scope of the present invention.
Claims (6)
1. An application of the circular RNA hsa _ circ _0001495 in preparing liver cancer diagnosis products.
2. The loop RNA hsa _ circ _0001495 according to claim 1, wherein the loop RNA hsa _ circ _0001495 is derived from the 12 th site of the long arm of human chromosome 5 and is generated by the reverse splicing and circularization of exons 6 to 7, and has a length of 378bp and the nucleic acid sequence of SEQ ID No.1.
3. The use of hsa _ circ _0001495 according to claim 1 in the manufacture of a product for diagnosing liver cancer, wherein said product for diagnosing liver cancer comprises at least PCR amplification primers used in detecting the expression level of hsa _ circ _0001495 by SYBR Green, taqMan probes, two-hybrid probes or multiplex probes.
4. The use of hsa _ circ _0001495 according to claim 1 in the manufacture of a product for the diagnosis of liver cancer, wherein said product for the diagnosis of liver cancer further comprises a chip, a kit, a strip or a high throughput sequencing platform.
5. The application of the circular RNA hsa _ circ _0001495 as a target in the development of anti-cancer drugs, which is characterized in that the anti-cancer drugs comprise gene drugs or chemical drugs for inhibiting the expression of hsa _ circ _ 0001495.
6. The use of the hsa _ circ _0001495 molecule as a target in the development of anti-cancer drugs according to claim 5, wherein said genetic or chemical drugs are used to treat liver, lung, colorectal, gastric or breast cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310066644.XA CN115927643A (en) | 2023-02-06 | 2023-02-06 | Application of hsa _ circ _0001495 molecule in liver cancer treatment |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202310066644.XA CN115927643A (en) | 2023-02-06 | 2023-02-06 | Application of hsa _ circ _0001495 molecule in liver cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
CN115927643A true CN115927643A (en) | 2023-04-07 |
Family
ID=86557837
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202310066644.XA Pending CN115927643A (en) | 2023-02-06 | 2023-02-06 | Application of hsa _ circ _0001495 molecule in liver cancer treatment |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115927643A (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109652548A (en) * | 2019-01-21 | 2019-04-19 | 首都医科大学附属北京朝阳医院 | Application of the circ-CCNB1 as gastric cancer and diagnosis of colorectal carcinoma biomarker and therapy target |
-
2023
- 2023-02-06 CN CN202310066644.XA patent/CN115927643A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109652548A (en) * | 2019-01-21 | 2019-04-19 | 首都医科大学附属北京朝阳医院 | Application of the circ-CCNB1 as gastric cancer and diagnosis of colorectal carcinoma biomarker and therapy target |
Non-Patent Citations (2)
Title |
---|
YAN-MING LIU等: "CircCCNB1 silencing acting as a miR-106b-5p sponge inhibited GPM6A expression to promote HCC progression by enhancing DYNC1I1 expression and activating the AKT/ERK signaling pathway", INT J BIOL SCI, vol. 18, no. 2, 1 January 2022 (2022-01-01), pages 637 - 651 * |
户平安等: "miR-144 CCNB1信号调节通路在肝癌增殖迁移和侵袭作用及相关机制的研究", 肝胆外科杂志, vol. 25, no. 6, 31 December 2017 (2017-12-31), pages 471 - 474 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Chen et al. | Exosome-derived microRNAs in oral squamous cell carcinomas impact disease prognosis | |
CN110066875B (en) | Application of long-chain non-coding RNA lncLCIR-1 as lung cancer molecular marker | |
Ou et al. | p53-Induced LINC00893 regulates RBFOX2 stability to suppress gastric cancer progression | |
WO2019237688A1 (en) | Application of niemann-pick c1 protein in diagnosis and treatment of cancer | |
CN112430665B (en) | Molecular biomarker for diagnosing and treating triple negative breast cancer and application thereof | |
CN108220446B (en) | Application of LINC01356 as molecular marker in gastric cancer | |
CN110283912A (en) | Application of the has-miR-3656 as esophageal squamous cell carcinoma molecular marker | |
CN111139298B (en) | Application of 4-LncRNA molecular label in lung cancer prognosis evaluation | |
CN110317878A (en) | A kind of long-chain non-coding RNA and its application for bladder cancer diagnosis and treatment monitoring | |
Liu et al. | Effects of miR-222 on cisplatin resistance of renal cancer cell strains and related mechanisms | |
Hu et al. | Down regulation of human positive coactivator 4 suppress tumorigenesis and lung metastasis of osteosarcoma | |
CN115927643A (en) | Application of hsa _ circ _0001495 molecule in liver cancer treatment | |
Zhang et al. | MiR-150 inhibits proliferation of mantle-cell lymphoma cells via regulation of MET | |
Sultan et al. | Exploring Small Nucleolar RNA Host Gene 3 as a Therapeutic Target in Breast Cancer Through Metabolic Reprogramming | |
CN110577952B (en) | Application of siRNA interfering long non-coding RNA in preparation of medicine for treating breast cancer | |
Fang et al. | MIIP inhibits malignant progression of hepatocellular carcinoma through regulating AKT. | |
CN113122638B (en) | Application of hsa-novel_circ_0006787 molecule in liver cancer treatment | |
CN111471682A (en) | Application of miR-23a as marker for diagnosing and treating gastric cancer pseudotube production | |
CN111534587A (en) | Molecular marker 5-tRF-His, breast cancer detection kit and application thereof | |
CN110643707A (en) | ESCC-related lncRNA LLNLR-299G3.1 and application thereof | |
CN112535726B (en) | Tumor marker AQUAPRIN 2 protein and application thereof | |
CN114164270B (en) | Application of CRIP2 in detecting resistance of prostate cancer to docetaxel and reversing resistance of prostate cancer to docetaxel | |
CN110408698B (en) | New diagnosis and treatment marker lncRNA-LALR1 for liver cancer and application thereof | |
WO2023082242A1 (en) | Use of ctd-2256p15.2 and encoding micropeptide thereof as target in development of tumor treatment drug | |
CN107723369B (en) | Application of SETD1B protein and coding gene thereof in diagnosis and treatment of liver cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |